Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy

We uncovered the neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) as a reservoir providing glutamate to promote cancer growth, and demonstrated that inhibition of NAAG hydrolysis by targeting glutamate carboxypeptidase II is a viable strategy for cancer therapy. Our study also suggests that NAAG...

Descripción completa

Detalles Bibliográficos
Autores principales: Asaka, Ryoichi, Le, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736126/
https://www.ncbi.nlm.nih.gov/pubmed/31528698
http://dx.doi.org/10.1080/23723556.2019.1627273
_version_ 1783450461329686528
author Asaka, Ryoichi
Le, Anne
author_facet Asaka, Ryoichi
Le, Anne
author_sort Asaka, Ryoichi
collection PubMed
description We uncovered the neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) as a reservoir providing glutamate to promote cancer growth, and demonstrated that inhibition of NAAG hydrolysis by targeting glutamate carboxypeptidase II is a viable strategy for cancer therapy. Our study also suggests that NAAG concentration in plasma could be a non-invasive measurement to monitor cancer progression.
format Online
Article
Text
id pubmed-6736126
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-67361262020-06-20 Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy Asaka, Ryoichi Le, Anne Mol Cell Oncol Author’s Views We uncovered the neurotransmitter N-acetyl-aspartyl-glutamate (NAAG) as a reservoir providing glutamate to promote cancer growth, and demonstrated that inhibition of NAAG hydrolysis by targeting glutamate carboxypeptidase II is a viable strategy for cancer therapy. Our study also suggests that NAAG concentration in plasma could be a non-invasive measurement to monitor cancer progression. Taylor & Francis 2019-06-20 /pmc/articles/PMC6736126/ /pubmed/31528698 http://dx.doi.org/10.1080/23723556.2019.1627273 Text en © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Asaka, Ryoichi
Le, Anne
Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title_full Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title_fullStr Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title_full_unstemmed Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title_short Dual role of N-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
title_sort dual role of n-acetyl-aspartyl-glutamate metabolism in cancer monitor and therapy
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736126/
https://www.ncbi.nlm.nih.gov/pubmed/31528698
http://dx.doi.org/10.1080/23723556.2019.1627273
work_keys_str_mv AT asakaryoichi dualroleofnacetylaspartylglutamatemetabolismincancermonitorandtherapy
AT leanne dualroleofnacetylaspartylglutamatemetabolismincancermonitorandtherapy

Ejemplares similares